Selected research
Industry Research
Antiasthmatic Drug Industry Research Report 2026
Market perspective
The global Antiasthmatic Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antiasthmatic Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antiasthmatic Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antiasthmatic Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antiasthmatic Drug include Ruiyang Pharmaceutical Co., Ltd, Novartis AG, Roche, Lunan Pharmaceutical Group Co., Ltd, Kaifeng Kangnuo Pharmaceutical Co., Ltd, GlaxoSmithKline, Fuhe Group, Chengdu Huayu Pharmaceutical Co., Ltd and AstraZeneca, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antiasthmatic Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antiasthmatic Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antiasthmatic Drug Market by Company
Ruiyang Pharmaceutical Co., Ltd
Novartis AG
Roche
Lunan Pharmaceutical Group Co., Ltd
Kaifeng Kangnuo Pharmaceutical Co., Ltd
GlaxoSmithKline
Fuhe Group
Chengdu Huayu Pharmaceutical Co., Ltd
AstraZeneca
Teva Pharmaceutical Industries Ltd
Mundipharma Pharmaceuticals Ltd.
MSD
Kyorin Pharmaceutical Co.,Ltd.
Kissei Pharmaceutical Co.Ltd.
Daiichi Sankyo Company Limited
Covis Pharmaceutical Inc
Chiesi GmbH
Boehringer Ingelheim Pharma GmbH&Co.KG
Akorn Pharmaceutical Co.Ltd.
ABC Farmaceutici Spa
Antiasthmatic Drug Segment by Type
Anti-allergic Antiasthmatic
Anti-inflammatory Antiasthmatic
Bronchodilators
Antiasthmatic Drug Segment by Application
Hospital
Clinic
Other
Antiasthmatic Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiasthmatic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antiasthmatic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiasthmatic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antiasthmatic Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Anti-allergic Antiasthmatic
- Anti-inflammatory Antiasthmatic
- Bronchodilators
Applications
- Hospital
- Clinic
- Other
Companies covered
- Ruiyang Pharmaceutical Co., Ltd
- Novartis AG
- Roche
- Lunan Pharmaceutical Group Co., Ltd
- Kaifeng Kangnuo Pharmaceutical Co., Ltd
- GlaxoSmithKline
- Fuhe Group
- Chengdu Huayu Pharmaceutical Co., Ltd
- AstraZeneca
- Teva Pharmaceutical Industries Ltd
- Mundipharma Pharmaceuticals Ltd.
- MSD
- Kyorin Pharmaceutical Co.,Ltd.
- Kissei Pharmaceutical Co.Ltd.
- Daiichi Sankyo Company Limited
- Covis Pharmaceutical Inc
- Chiesi GmbH
- Boehringer Ingelheim Pharma GmbH&Co.KG
- Akorn Pharmaceutical Co.Ltd.
- ABC Farmaceutici Spa
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antiasthmatic Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Anti-allergic Antiasthmatic
- 2.2.3 Anti-inflammatory Antiasthmatic
- 2.2.4 Bronchodilators
- 2.3 Antiasthmatic Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Antiasthmatic Drug Breakdown Data by Type
- 3.1 Global Antiasthmatic Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Antiasthmatic Drug Forecasted Market Size by Type (2027-2032)
4 Antiasthmatic Drug Breakdown Data by Application
- 4.1 Global Antiasthmatic Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Antiasthmatic Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antiasthmatic Drug Market Perspective (2021-2032)
- 5.2 Global Antiasthmatic Drug Growth Trends by Region
- 5.2.1 Global Antiasthmatic Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antiasthmatic Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Antiasthmatic Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Antiasthmatic Drug Market Dynamics
- 5.3.1 Antiasthmatic Drug Industry Trends
- 5.3.2 Antiasthmatic Drug Market Drivers
- 5.3.3 Antiasthmatic Drug Market Challenges
- 5.3.4 Antiasthmatic Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antiasthmatic Drug Players by Revenue
- 6.1.1 Global Top Antiasthmatic Drug Players by Revenue (2021-2026)
- 6.1.2 Global Antiasthmatic Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Antiasthmatic Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antiasthmatic Drug Head Office and Area Served
- 6.4 Global Antiasthmatic Drug Players, Product Type & Application
- 6.5 Global Antiasthmatic Drug Manufacturers Established Date
- 6.6 Global Antiasthmatic Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antiasthmatic Drug Market Size (2021-2032)
- 7.2 North America Antiasthmatic Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antiasthmatic Drug Market Size by Country (2021-2026)
- 7.4 North America Antiasthmatic Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antiasthmatic Drug Market Size (2021-2032)
- 8.2 Europe Antiasthmatic Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antiasthmatic Drug Market Size by Country (2021-2026)
- 8.4 Europe Antiasthmatic Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antiasthmatic Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Antiasthmatic Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antiasthmatic Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antiasthmatic Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antiasthmatic Drug Market Size (2021-2032)
- 10.2 South America Antiasthmatic Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antiasthmatic Drug Market Size by Country (2021-2026)
- 10.4 South America Antiasthmatic Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antiasthmatic Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Antiasthmatic Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antiasthmatic Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antiasthmatic Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Ruiyang Pharmaceutical Co., Ltd
- 12.1.1 Ruiyang Pharmaceutical Co., Ltd Company Information
- 12.1.2 Ruiyang Pharmaceutical Co., Ltd Business Overview
- 12.1.3 Ruiyang Pharmaceutical Co., Ltd Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.1.4 Ruiyang Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
- 12.1.5 Ruiyang Pharmaceutical Co., Ltd Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.2.4 Novartis AG Antiasthmatic Drug Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Roche
- 12.3.1 Roche Company Information
- 12.3.2 Roche Business Overview
- 12.3.3 Roche Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.3.4 Roche Antiasthmatic Drug Product Portfolio
- 12.3.5 Roche Recent Developments
- 12.4 Lunan Pharmaceutical Group Co., Ltd
- 12.4.1 Lunan Pharmaceutical Group Co., Ltd Company Information
- 12.4.2 Lunan Pharmaceutical Group Co., Ltd Business Overview
- 12.4.3 Lunan Pharmaceutical Group Co., Ltd Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.4.4 Lunan Pharmaceutical Group Co., Ltd Antiasthmatic Drug Product Portfolio
- 12.4.5 Lunan Pharmaceutical Group Co., Ltd Recent Developments
- 12.5 Kaifeng Kangnuo Pharmaceutical Co., Ltd
- 12.5.1 Kaifeng Kangnuo Pharmaceutical Co., Ltd Company Information
- 12.5.2 Kaifeng Kangnuo Pharmaceutical Co., Ltd Business Overview
- 12.5.3 Kaifeng Kangnuo Pharmaceutical Co., Ltd Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.5.4 Kaifeng Kangnuo Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
- 12.5.5 Kaifeng Kangnuo Pharmaceutical Co., Ltd Recent Developments
- 12.6 GlaxoSmithKline
- 12.6.1 GlaxoSmithKline Company Information
- 12.6.2 GlaxoSmithKline Business Overview
- 12.6.3 GlaxoSmithKline Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.6.4 GlaxoSmithKline Antiasthmatic Drug Product Portfolio
- 12.6.5 GlaxoSmithKline Recent Developments
- 12.7 Fuhe Group
- 12.7.1 Fuhe Group Company Information
- 12.7.2 Fuhe Group Business Overview
- 12.7.3 Fuhe Group Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.7.4 Fuhe Group Antiasthmatic Drug Product Portfolio
- 12.7.5 Fuhe Group Recent Developments
- 12.8 Chengdu Huayu Pharmaceutical Co., Ltd
- 12.8.1 Chengdu Huayu Pharmaceutical Co., Ltd Company Information
- 12.8.2 Chengdu Huayu Pharmaceutical Co., Ltd Business Overview
- 12.8.3 Chengdu Huayu Pharmaceutical Co., Ltd Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.8.4 Chengdu Huayu Pharmaceutical Co., Ltd Antiasthmatic Drug Product Portfolio
- 12.8.5 Chengdu Huayu Pharmaceutical Co., Ltd Recent Developments
- 12.9 AstraZeneca
- 12.9.1 AstraZeneca Company Information
- 12.9.2 AstraZeneca Business Overview
- 12.9.3 AstraZeneca Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.9.4 AstraZeneca Antiasthmatic Drug Product Portfolio
- 12.9.5 AstraZeneca Recent Developments
- 12.10 Teva Pharmaceutical Industries Ltd
- 12.10.1 Teva Pharmaceutical Industries Ltd Company Information
- 12.10.2 Teva Pharmaceutical Industries Ltd Business Overview
- 12.10.3 Teva Pharmaceutical Industries Ltd Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.10.4 Teva Pharmaceutical Industries Ltd Antiasthmatic Drug Product Portfolio
- 12.10.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 12.11 Mundipharma Pharmaceuticals Ltd.
- 12.11.1 Mundipharma Pharmaceuticals Ltd. Company Information
- 12.11.2 Mundipharma Pharmaceuticals Ltd. Business Overview
- 12.11.3 Mundipharma Pharmaceuticals Ltd. Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.11.4 Mundipharma Pharmaceuticals Ltd. Antiasthmatic Drug Product Portfolio
- 12.11.5 Mundipharma Pharmaceuticals Ltd. Recent Developments
- 12.12 MSD
- 12.12.1 MSD Company Information
- 12.12.2 MSD Business Overview
- 12.12.3 MSD Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.12.4 MSD Antiasthmatic Drug Product Portfolio
- 12.12.5 MSD Recent Developments
- 12.13 Kyorin Pharmaceutical Co.,Ltd.
- 12.13.1 Kyorin Pharmaceutical Co.,Ltd. Company Information
- 12.13.2 Kyorin Pharmaceutical Co.,Ltd. Business Overview
- 12.13.3 Kyorin Pharmaceutical Co.,Ltd. Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.13.4 Kyorin Pharmaceutical Co.,Ltd. Antiasthmatic Drug Product Portfolio
- 12.13.5 Kyorin Pharmaceutical Co.,Ltd. Recent Developments
- 12.14 Kissei Pharmaceutical Co.Ltd.
- 12.14.1 Kissei Pharmaceutical Co.Ltd. Company Information
- 12.14.2 Kissei Pharmaceutical Co.Ltd. Business Overview
- 12.14.3 Kissei Pharmaceutical Co.Ltd. Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.14.4 Kissei Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio
- 12.14.5 Kissei Pharmaceutical Co.Ltd. Recent Developments
- 12.15 Daiichi Sankyo Company Limited
- 12.15.1 Daiichi Sankyo Company Limited Company Information
- 12.15.2 Daiichi Sankyo Company Limited Business Overview
- 12.15.3 Daiichi Sankyo Company Limited Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.15.4 Daiichi Sankyo Company Limited Antiasthmatic Drug Product Portfolio
- 12.15.5 Daiichi Sankyo Company Limited Recent Developments
- 12.16 Covis Pharmaceutical Inc
- 12.16.1 Covis Pharmaceutical Inc Company Information
- 12.16.2 Covis Pharmaceutical Inc Business Overview
- 12.16.3 Covis Pharmaceutical Inc Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.16.4 Covis Pharmaceutical Inc Antiasthmatic Drug Product Portfolio
- 12.16.5 Covis Pharmaceutical Inc Recent Developments
- 12.17 Chiesi GmbH
- 12.17.1 Chiesi GmbH Company Information
- 12.17.2 Chiesi GmbH Business Overview
- 12.17.3 Chiesi GmbH Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.17.4 Chiesi GmbH Antiasthmatic Drug Product Portfolio
- 12.17.5 Chiesi GmbH Recent Developments
- 12.18 Boehringer Ingelheim Pharma GmbH&Co.KG
- 12.18.1 Boehringer Ingelheim Pharma GmbH&Co.KG Company Information
- 12.18.2 Boehringer Ingelheim Pharma GmbH&Co.KG Business Overview
- 12.18.3 Boehringer Ingelheim Pharma GmbH&Co.KG Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.18.4 Boehringer Ingelheim Pharma GmbH&Co.KG Antiasthmatic Drug Product Portfolio
- 12.18.5 Boehringer Ingelheim Pharma GmbH&Co.KG Recent Developments
- 12.19 Akorn Pharmaceutical Co.Ltd.
- 12.19.1 Akorn Pharmaceutical Co.Ltd. Company Information
- 12.19.2 Akorn Pharmaceutical Co.Ltd. Business Overview
- 12.19.3 Akorn Pharmaceutical Co.Ltd. Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.19.4 Akorn Pharmaceutical Co.Ltd. Antiasthmatic Drug Product Portfolio
- 12.19.5 Akorn Pharmaceutical Co.Ltd. Recent Developments
- 12.20 ABC Farmaceutici Spa
- 12.20.1 ABC Farmaceutici Spa Company Information
- 12.20.2 ABC Farmaceutici Spa Business Overview
- 12.20.3 ABC Farmaceutici Spa Revenue in Antiasthmatic Drug Business (2021-2026)
- 12.20.4 ABC Farmaceutici Spa Antiasthmatic Drug Product Portfolio
- 12.20.5 ABC Farmaceutici Spa Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst